LCZ 696

DRUG6 trials

Sponsors

Mayo Clinic, The Second Affiliated Hospital of Harbin Medical University, Mohammed Alnims, National Medical Research Center for Cardiology, Ministry of Health of Russian Federation, Vanderbilt University Medical Center

Conditions

CKDDiabetes Mellitus, Type 2Diastolic DysfunctionEssential HypertensionHeart FailureHeart Failure With Reduced Ejection Fraction

Early Phase 1

Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease（CKD）Patients With Heart Failure

The Second Affiliated Hospital of Harbin Medical UniversityCKD

Start: 2018-12-30End: 2019-06-15Target: 30Updated: 2018-12-11

Phase 2

PDD in Type 2 Diabetes w/wo Diastolic Dysfunction

CompletedNCT03744975

Mayo ClinicDiabetes Mellitus, Type 2, Diastolic Dysfunction

Start: 2018-05-01End: 2025-08-27Updated: 2025-12-12

LCZ696 in Advanced LV Hypertrophy and HFpEF

CompletedNCT03928158

National Medical Research Center for Cardiology, Ministry of Health of Russian FederationEssential Hypertension, Heart Failure

Start: 2019-05-31End: 2023-12-31Updated: 2025-05-25

Phase 4

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

CompletedNCT04113109

Vanderbilt University Medical CenterHeart Failure

Start: 2019-11-01End: 2025-07-30Updated: 2026-08-11

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

CompletedNCT04649229

Yale UniversityHeart Failure

Start: 2021-05-27End: 2025-05-22Updated: 2026-03-17

Unknown Phase

Six Months Clinical and Echocardiographic Outcome of ARNI LCZ696 Therapy in HFrEF Patients

CompletedNCT03816306

Mohammed AlnimsHeart Failure With Reduced Ejection Fraction

Start: 2018-06-01End: 2019-12-01Updated: 2020-01-18

Related Papers

Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure.

2026-04-24